Low Plasma Level of Cathelicidin Antimicrobial Peptide (hCAP18) Predicts Increased Infectious Disease Mortality in Patients Undergoing Hemodialysis | Zendy

Adrian F. Gombart | Zendy; Ishir Bhan | Zendy; Niels Borregaard | Zendy; Hector Tamez | Zendy; Carlos A. Camargo | Zendy; H. Phillip Koeffler | Zendy; Ravi Thadhani | Zendy

Open Access

Low Plasma Level of Cathelicidin Antimicrobial Peptide (hCAP18) Predicts Increased Infectious Disease Mortality in Patients Undergoing Hemodialysis

Author(s) -

Adrian F. Gombart,

Ishir Bhan,

Niels Borregaard,

Hector Tamez,

Carlos A. Camargo,

H. Phillip Koeffler,

Ravi Thadhani

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/596314

Subject(s) - cathelicidin , medicine , hemodialysis , antimicrobial , infectious disease (medical specialty) , vitamin d and neurology , end stage renal disease , peptide , antimicrobial peptides , immunology , disease , microbiology and biotechnology , biology , biochemistry

Human cathelicidin antimicrobial protein (hCAP18) is an antimicrobial and immunomodulatory peptide that has pleiotropic effects and is transcriptionally regulated by vitamin D. Because the administration of vitamin D analogues has been linked to decreased mortality among patients with end-stage renal disease, we hypothesized that low hCAP18 levels would identify those who are at increased risk of death attributable to infection while undergoing hemodialysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research